B
Bull
Bull · 25%ADGM
$1.53
Precio del escenario
$0.511
-0.009 (-1.79%)Al cierre
Loading chart…
- High
- 0.543
- Open
- 0.515
- VWAP
- 0.52
- Vol
- 230.47K
- Mkt Cap
- —
- Low
- 0.500
- Amount
- 119.39K
- EV/EBITDA, TTM
- 0.00
Adagio Medical Holdings, Inc. is a medical device company. The Company is focused on developing and commercializing products for the treatment of cardiac arrhythmias with catheter-based ultra-low temperature ablation (ULTA) technology, formerly known as ultra-low temperature cryoablation (ULTC) technology. Its initial focus is on the treatment of ventricular tachycardia (VT), which is a rapid, abnormal heart rhythm, or arrhythmia, that originates in the heart’s lower chambers, or ventricles, potentially leading to impaired blood flow and, if sustained, it can be fatal. Its ULTA products are purpose-built to treat patients with VT and are designed to address the unique anatomy of the ventricle and the specific needs of the VT patient. Its catheters and consoles are designed to create titratable, large, durable, deep lesions within the ventricle through a stable, endocardial or inside the heart approach with no required irrigation.
AI analysis of Adagio Medical Holdings Inc (ADGM)
sellAdagio Medical Holdings Inc is not a good buy right now due to its current price of $0.51, a significantly low RSI of 20.16 indicating oversold conditions, and a staggering 68.84% decline over the past year. The main risk is its negative net income of -$7 million reported for Q1 2026, which raises concerns about its financial sustainability.
Métricas de valoración
The current forward P/E ratio for Adagio Medical Holdings Inc (ADGM) is 0.00, compared to its 5-year average forward P/E of -0.07.
Alphio AI Price Scenarios for ADGM
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding ADGM
Cronología de eventos
Noticias
9.508-11NewsfilterAdagio Medical Reports Q2 2026 Financial Results and Key Developments
5.008-04NASDAQ.COMAdagio Medical Successfully Treats First Patient with Next-Gen Ablation System
- 8.505-21Newsfilter
Adagio Submits PMA Application for vCLAS System
9.505-12seekingalphaAdagio Medical Reports Q1 Financial Results with Reduced Losses
- 2.004-26Newsfilter
FULCRUM-VT Trial Demonstrates Effectiveness of Cardiac Ablation Technology
ADGM FAQ — answered by Alphio AI
Adagio Medical Holdings, Inc. is a medical device company. The Company is focused on developing and commercializing products for the treatment of cardiac arrhythmias with catheter-based ultra-low temperature ablation (ULTA) technology, formerly known as ultra-low temperature cryoablation (ULTC) technology. Its initial focus is on the treatment of ventricular tachycardia (VT), which is a rapid, abnormal heart rhythm, or arrhythmia, that originates in the heart’s lower chambers, or ventricles, potentially leading to impaired blood flow and, if sustained, it can be fatal. Its ULTA products are purpose-built to treat patients with VT and are designed to address the unique anatomy of the ventricle and the specific needs of the VT patient. Its catheters and consoles are designed to create titratable, large, durable, deep lesions within the ventricle through a stable, endocardial or inside the heart approach with no required irrigation. It operates in the Healthcare sector.
Adagio Medical Holdings Inc is not a good buy right now due to its current price of $0.51, a significantly low RSI of 20.16 indicating oversold conditions, and a staggering 68.84% decline over the past year. The main risk is its negative net income of -$7 million reported for Q1 2026, which raises concerns about its financial sustainability.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.